HLB Pep Co., Ltd. (KOSDAQ:196300)

Market Cap	75.18B +14.3%
Revenue (ttm)	4.89B -20.0%
Net Income	-6.02B
EPS	-775.40
Shares Out	9.29M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	35,356
Average Volume	20,052
Open	8,010.00
Previous Close	n/a
Day's Range	7,960.00 - 8,300.00
52-Week Range	5,580.00 - 14,240.00
Beta	0.28
RSI	52.92
Earnings Date	n/a

About HLB Pep

HLB Pep Co., Ltd., a bio-venture company, engages in the manufacture and sale of peptide biomaterials and drug raw materials in South Korea and internationally. It offers GMP, generic, custom, and catalog peptides, as well as offers other services. The company develops AGM-130, which is in Phase I for the treatment of triple negative breast cancer. In addition, its pre-clinical products include AGM-331 targeted for anti-cancer therapy; AGM-380 indicated for the treatment of viral infection; and AGM-290 indicated for the treatment of infections ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2000
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 196300

Financial Performance

In 2024, HLB Pep's revenue was 6.23 billion, an increase of 11.02% compared to the previous year's 5.61 billion. Losses were -6.79 billion, -25.18% less than in 2023.